Overcoming barriers to patient adherence: the case for develo** innovative drug delivery systems
Poor medication adherence is a pervasive issue with considerable health and
socioeconomic consequences. Although the underlying reasons are generally understood …
socioeconomic consequences. Although the underlying reasons are generally understood …
The promise of improved adherence with long-acting antiretroviral therapy: what are the data?
As with other chronic conditions, adherence to daily medications remains a challenge for
many individuals living with HIV due to structural, behavioral, and social barriers …
many individuals living with HIV due to structural, behavioral, and social barriers …
Week 96 extension results of a phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment
S Swindells, T Lutz, L Van Zyl, N Porteiro, M Stoll… - Aids, 2022 - journals.lww.com
Background: ATLAS (NCT02951052), a phase 3, multicenter, open-label study,
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
demonstrated that switching to injectable cabotegravir (CAB) with rilpivirine (RPV) long …
Medical mistrust among women with intersecting marginalized identities: a sco** review
IK Ho, TA Sheldon, E Botelho - Ethnicity & Health, 2022 - Taylor & Francis
The purpose of this sco** review is to synthesize knowledge about medical mistrust and
health among women who occupy other marginalized identities; namely women who also …
health among women who occupy other marginalized identities; namely women who also …
Patient-reported outcomes through 1 year of an HIV-1 clinical trial evaluating long-acting cabotegravir and rilpivirine administered every 4 or 8 weeks (ATLAS-2M)
V Chounta, ET Overton, A Mills, S Swindells… - The Patient-Patient …, 2021 - Springer
Background Advances in HIV-1 therapeutics have led to the development of a range of daily
oral treatment regimens, which share similar high efficacy rates. Consequently, more …
oral treatment regimens, which share similar high efficacy rates. Consequently, more …
Perspectives on preparing for long-acting injectable treatment for HIV among consumer, clinical and nonclinical stakeholders: a qualitative study exploring the …
Long-acting injectable (LAI) antiretroviral therapy (ART) is a novel HIV treatment option for
people with HIV. The first LAI ART regimen for HIV treatment received regulatory approval in …
people with HIV. The first LAI ART regimen for HIV treatment received regulatory approval in …
Barriers to uptake of long-acting antiretroviral products for treatment and prevention of human immunodeficiency virus (HIV) in high-income countries
SE Cooper, J Rosenblatt… - Clinical Infectious Diseases, 2022 - academic.oup.com
Long-acting injectable antiretroviral therapy (LAI-ART) for the treatment and prevention of
human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by …
human immunodeficiency virus (HIV) holds great potential to shift treatment paradigms by …
The LAIs are coming! Implementation science considerations for long-acting injectable antiretroviral therapy in the United States: a sco** review
Long-acting injectable antiretroviral therapy (LAI-ART) is one of the latest advancements in
HIV control with the potential to overcome oral ART barriers to adherence. The objective of …
HIV control with the potential to overcome oral ART barriers to adherence. The objective of …
A qualitative exploration of women's interest in long-acting injectable antiretroviral therapy across six cities in the women's interagency HIV study: intersections with …
MM Philbin, C Parish, S Bergen, D Kerrigan… - AIDS patient care and …, 2021 - liebertpub.com
Medications for antiretroviral therapy (ART) and preexposure prophylaxis (PrEP) are
currently daily pill regimens, which pose barriers to long-term adherence. Long-acting …
currently daily pill regimens, which pose barriers to long-term adherence. Long-acting …
Impact of long-acting therapies on the global HIV epidemic
Long-acting antiretroviral drugs have emerged as exciting treatment and preexposure
prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may …
prophylaxis (PrEP) options for people with HIV and at risk of HIV. Long-acting regimens may …